Dubovsky Filip 4
4 · NOVAVAX INC · Filed Jun 20, 2024
Insider Transaction Report
Form 4
NOVAVAX INCNVAX
Dubovsky Filip
President, R&D
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-06-17$6.09/sh−12,500$76,125→ 37,500 totalExercise: $6.09Exp: 2033-03-27→ Common Stock (12,500 underlying) - Exercise/Conversion
Common Stock
2024-06-17$6.97/sh+1,404$9,786→ 68,017 total - Exercise/Conversion
Common Stock
2024-06-17$6.09/sh+12,500$76,125→ 80,517 total - Sale
Common Stock
2024-06-17$14.46/sh−12,500$180,750→ 68,017 total - Sale
Common Stock
2024-06-17$14.54/sh−1,404$20,414→ 66,613 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-06-17$6.97/sh−1,404$9,786→ 46,324 totalExercise: $6.97Exp: 2033-03-07→ Common Stock (1,404 underlying)
Footnotes (1)
- [F1]Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.